[Cannabinoid Drugs in the Treatment of Psychiatric Disorders - Data from the German Federal Institute for Drugs and Medical Devices].

Felix WülfingGabriele Schmidt-WolfPeter Cremer-SchaefferKathlen PriebeNikola Schoofs

Published in: Psychiatrische Praxis (2024)

Most patients with psychiatric disorders received cannabinoid drugs for pain. The evidence from randomized controlled clinical trials for the use of cannabinoid drugs in psychiatric indications is weak.

Keyphrases

clinical trial
chronic pain
open label
double blind
mental health
randomized controlled trial
phase iii
pain management
drug induced
electronic health record
machine learning
spinal cord
big data
replacement therapy